Logo image
Salvage regional therapy using hepatic artery infusion pump in unresectable chemotherapy resistant colorectal liver metastases
Journal article   Peer reviewed

Salvage regional therapy using hepatic artery infusion pump in unresectable chemotherapy resistant colorectal liver metastases

American Journal of Surgery, Vol.223(6)
2022

Abstract

Antineoplastic Combined Chemotherapy Protocols Colorectal Neoplasms Hepatic Artery Humans Infusion Pumps, Implantable Infusions, Intra-Arterial Liver Neoplasms Retrospective Studies albumin alkaline phosphatase aspartate aminotransferase B Raf kinase bevacizumab bilirubin capecitabine cetuximab drug floxuridine fluorouracil folfox folinic acid irinotecan oxaliplatin panitumumab regorafenib tipiracil plus trifluridine unclassified drug antineoplastic agent ablation therapy adult Article cancer patient chemotherapy clinical article colorectal cancer colorectal liver metastasis computer assisted tomography duodenum ulcer external beam radiotherapy female hemorrhagic shock hepatectomy hepatic artery human liver disease liver function test liver injury male microsatellite instability middle aged nuclear magnetic resonance imaging oncogene ras overall survival peptic ulcer progression free survival retrospective study salvage regional therapy salvage therapy treatment outcome x-ray computed tomography colorectal tumor hepatic artery implantable infusion pump intraarterial drug administration liver tumor pathology
Background: Little is known about the influence of hepatic artery infusion pump (HAIP) therapy in the setting of chemotherapy resistant hepatic disease in the era of modern systemic therapies. Methods: Patients who underwent HAIP therapy for chemotherapy resistant and unresectable colorectal liver metastases (CRLM) were reviewed retrospectively. Results: A total of 25 patients met inclusion criteria. 52% had isolated CRLM and 92% had five or more metastatic lesions. Partial response was noted in 40% of patients. Median hepatic progression-free survival (PFS) was 7 months in those with extrahepatic disease versus 6 months in those with isolated CRLM at the time of HAIP placement (p = 0.75). Median overall survival was 8 months in patients with extrahepatic disease and 14 months in patients with isolated CRLM (p = 0.06). Conclusions: Our findings are comparable to published data and augment the literature which supports HAIP use in chemotherapy-resistant, liver-predominant metastatic colorectal cancer patients. © 2021 Elsevier Inc.

Metrics

6 Record Views

Details

Logo image